CJC-1295 DAC

CJC-1295 with DAC is a quadruple-substituted GHRH(1-29) analog with a maleimidopropionic acid linker that binds covalently to serum albumin, extending the half-life from minutes to approximately six to eight days.

Albumin binding protects the peptide against DPP-4 cleavage and renal clearance, producing a sustained elevation of GH and IGF-1 rather than discrete pulses. This 'bleed' effect distinguishes DAC variants from short-acting GHRH analogs such as CJC-1295 without DAC.

Store the sealed lyophilized vial at 2-8 °C, protected from light; brief exposure to room temperature during shipping is generally tolerated. Refrigerate after reconstitution at 2-8 °C and use within the period supported by stability data for the substance (typically 2-4 weeks). Avoid repeated freeze-thaw cycles: each cycle increases the risk of aggregation and hydrolysis of the peptide bond. Do not shake the vial; swirl gently and direct the liquid stream against the glass wall rather than at the powder cake.

• Sealed lyophilized vial, stored as supplied
• Bacteriostatic water (0.9% benzyl alcohol) for reconstitution
• Insulin syringes (29-31G, 0.5 mL / 100 units)
• Reconstitution syringe (1-3 mL, 21-23G needle)
• 70% isopropyl alcohol swabs
• Sharps container for used needles
• Labels and a logbook for batch, date and volume

Phase I research reported dose-dependent GH increases of 2-10 fold and sustained IGF-1 elevation up to two weeks after a single dose, with generally acceptable tolerability. Reported effects include transient flushing, injection-site reactions and headache. Sustained non-pulsatile GH exposure is a theoretical concern for insulin sensitivity.

Wash your hands, then disinfect the vial septum and the injection site with 70% isopropyl alcohol and allow both to air dry. Draw up the intended volume, remove air bubbles and pinch a subcutaneous skin fold. Insert at a 45-90° angle depending on fat thickness, aspiration is not required for subcutaneous administration, and inject slowly. Withdraw the needle, apply light pressure and discard the needle in a sharps container. Rotate injection sites systematically (abdominal quadrants, flanks, thighs) to prevent lipohypertrophy and local irritation.

Peptide research protocols are studied against a background of adequate protein intake (approximately 1.6-2.2 g/kg/day in the training literature), consistent sleep of 7-9 hours, and controlled training load. Sleep deprivation and chronic psychological stress both dampen growth hormone pulsatility and disrupt tissue remodeling, complicating the interpretation of any observed effect. Alcohol, smoking and large caloric deficits are likewise documented modifiers of recovery outcomes.

1. Teichman S.L. et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295. J Clin Endocrinol Metab, 2006.
2. Ionescu M., Frohman L.A. Pulsatile secretion of GH persists during continuous GHRH stimulation. J Clin Endocrinol Metab, 2006.
3. Jette L. et al. Human GRF analog with albumin binding. Endocrinology, 2005.